Us Neurovascular Devices Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The North American neurovascular devices market covers a range of interventional and surgical products designed to treat complex cerebrovascular diseases through minimally invasive endovascular approaches. The market includes embolization coils, neurovascular stents, flow diverters, aspiration thrombectomy systems, and balloon catheters used in procedures such as mechanical thrombectomy for acute ischemic stroke and coiling or flow diversion for aneurysm treatment. The United States represents the vast majority of the North American market, supported by a high burden of neurovascular disease, strong hospital investment in hybrid operating rooms and angiography suites, and widespread insurance coverage for neurointerventional procedures.

• •Market valued at approximately $1.82 billion in 2025 across North America
• •Products include embolization coils, stents, flow diverters, aspiration devices, and balloons
• •Procedures cover acute ischemic stroke treatment, aneurysm repair, AVM embolization, and intracranial atherosclerosis management
• •Growth trajectory supported by aging population and rising neurovascular disease prevalence

The market is primarily driven by the rising incidence of stroke and cerebral aneurysms, conditions that become more prevalent with advancing age, combined with the growing elderly population in the United States and Canada. Technological advancements in minimally invasive devices, particularly in mechanical thrombectomy for large vessel occlusion strokes, have significantly expanded the treatable patient population and improved clinical outcomes. Favorable reimbursement policies from Medicare, Medicaid, and private insurers for neurointerventional procedures have facilitated broader adoption of these devices across hospital networks of all sizes.

• •Aging population driving increased incidence of aneurysms, strokes, and other cerebrovascular conditions
• •Mechanical thrombectomy adoption for large vessel occlusion strokes has expanded since 2015 clinical trials
• •Favorable reimbursement environment across Medicare, Medicaid, and private payers supports procedure volume growth
• •Continued innovation in device design, including softer coils and low-profile delivery systems, broadens treatable patient populations

By product type, the market is segmented into coils and bare metal stents, flow diverters, embolic protection devices, balloon catheters, and thrombectomy devices, with coils and stent-assisted coiling representing the largest segment for aneurysm treatment. Ischemic stroke treatment devices, particularly aspiration and stent retriever thrombectomy systems, have been the fastest-growing segment following clinical validation of endovascular therapy. Geographically, the United States accounts for the overwhelming majority of the North American market, with Canada representing a smaller but growing segment driven by increasing procedural adoption and healthcare system investment.

• •United States dominates North America, driven by high procedure volumes and advanced hospital infrastructure
• •Canada shows emerging growth through expanding access to neurointerventional procedures
• •Ischemic stroke thrombectomy devices represent the fastest-growing product segment
• •Hospital catheterization labs and comprehensive stroke centers are the primary end-user environments

What are the recent trends and outlook?

The market is moving toward smaller-profile delivery systems that enable treatment of more distal and challenging vascular anatomies, as well as bioabsorbable and drug-eluting technologies designed to improve long-term outcomes. Artificial intelligence-assisted imaging and navigation tools are being integrated into neurointerventional workflows to improve procedural precision and reduce radiation exposure. Over the forecast period, the market is expected to maintain steady single-digit growth, supported by ongoing clinical evidence generation, expansion of mechanical thrombectomy to extended time windows, and continued adoption of advanced flow diversion technology for wide-necked aneurysms.

• •Low-profile delivery systems and distal access technologies are enabling treatment of more complex vascular anatomies
• •AI-assisted imaging and navigation are being adopted to improve procedural accuracy and operator safety
• •Expanded time windows for mechanical thrombectomy are broadening the addressable ischemic stroke patient population
• •Steady 3.58% CAGR expected as bioabsorbable technologies and drug-eluting devices move through clinical development